Myeloid Leukemia Clinical Trials

55 clinical trials for Myeloid Leukemia across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Halt Aging in Survivors of Blood Cancers — RECRUITING · NA
• Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia — RECRUITING · PHASE1
• Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors — RECRUITING · PHASE2
• Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL — RECRUITING · PHASE1
• Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT — RECRUITING · PHASE2
• A RANDOMIZED PHASE II STUDY COMPARING CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME, CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND (DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX IN PATIENTS AGED 59 OR YOUNGER WHO ARE CONSIDERED HIGH-RISK (ADVERSE) ACUTE MYELOID LEUKEMIA AS DETERMINED BY MYELOMATCH; A MYELOMATCH CLINICAL TRIAL — RECRUITING · PHASE2
• A GLOBAL MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 3 REGISTRATIONAL STUDY OF OLVEREMBATINIB (HQP1351) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (POLARIS-2) — RECRUITING · PHASE3
• A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL — RECRUITING · PHASE2
• A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE — RECRUITING · PHASE3
• A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE ACTIVITY, SAFETY AND PHARMACOKINETICS OF LENALIDOMIDE (REVLIMID®) IN PEDIATRIC SUBJECTS FROM 1 TO <= 18 YEARS OF AGE WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA — RECRUITING · PHASE2
• Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland — COMPLETED
• A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML — NOT_YET_RECRUITING · PHASE1
• Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies — COMPLETED · PHASE2
• Integrated Actionable Aging Assessment for Cancer Patients Pilot — ACTIVE_NOT_RECRUITING · NA
• Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML — NOT_YET_RECRUITING · PHASE2
• IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation — COMPLETED · PHASE1
• An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib Tablets 100 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with Bosulif (bosutinib) 100 mg, Manufactured and Packed by: Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee, Freiburg, Germany, Imported by: Pfizer Brasil Ltda. Rodovia Presidente Castelo Branco, nº32501, km 32.5 CEP 06696-000 – Itapevi – SP, in healthy — OTHER · PHASE1
• FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia — COMPLETED · PHASE1
• Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML — WITHDRAWN
• A MULTICENTER, OPEN-LABEL, DOSE-FINDING CLINICAL TRIAL TO ASSESS THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL EFFICACY OF RVU120 IN COMBINATION WITH VENETOCLAX IN PARTICIPANTS WITH ACUTE MYELOID LEUKEMIA WHO FAILED PRIOR THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT (RIVER-81) — NOT_YET_RECRUITING
• Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients — COMPLETED · PHASE2
• Frequency and Risk Factors of Acute Myeloid Leukemia — OTHER
• Study of IMC-EB10 in Participant With Leukemia — TERMINATED · PHASE1
• Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor — TERMINATED · PHASE2
• Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies — TERMINATED · PHASE1
• NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents — COMPLETED · PHASE2
• Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults — COMPLETED · PHASE2
• Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies — OTHER · PHASE1
• Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation — COMPLETED · NA
• Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery — COMPLETED · NA
• Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation — OTHER
• Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT — COMPLETED · NA
• Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia — COMPLETED · PHASE1
• AN OPEN-LABEL, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF CFI-400945 FUMARATE ADMINISTERED ORALLY TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME — COMPLETED
• A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS62P1 GIVEN AS MONOTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) — COMPLETED · PHASE1
• A PHASE IB TRIAL WITH MK-8628, A SMALL MOLECULE INHIBITOR OF THE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN SUBJECTS WITH SELECTED HEMATOLOGIC MALIGNANCIES — COMPLETED · PHASE1
• A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND ADMINISTERED AS CONTINUATION THERAPY IN SUBJECTS L8 TO 75 YEARS OLD WITH NEWLY DIAGNOSED FLT3- ITO(+) ACUTE MYELOID LEUKEMIA (QUANTUM-FIRST) — COMPLETED · PHASE3
• A PHASE 1/2 STUDY OF SL-401 AS CONSOLIDATION THERAPY FOR ADULT PATIENTS WITH ADVERSE RISK ACUTE MYELOID LEUKEMIA IN FIRST CR, AND/OR EVIDENCE OF MINIMAL RESIDUAL DISEASE (MRD) IN FIRST CR — NOT_YET_RECRUITING · PHASE1
• Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine — OTHER · NA
• A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF GSK2879552 GIVEN ORALLY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA. — COMPLETED · PHASE1
• A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) VERSUS SPECIFIED PHYSICIAN'S CHOICE IN PATIENTS ? 60 YEARS OLD WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY AND/OR TRANSPLANTATION [SOPRA STUDY: SELINEXOR (KPT-330) IN OLDER PATIENTS WITH RELAPSED AML] — COMPLETED · PHASE2
• A PHASE I TRIAL EVALUATING ORAL THIORIDAZINE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE IN PATIENTS S5 YEARS AND OLDER WITH ACUTE MYELOID LEUKEMIA WHO HAVE RELAPSED OR HAVE REFRACTORY DISEASE (THORIDAL) — COMPLETED · PHASE1
• A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY — COMPLETED · PHASE1
• Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents — OTHER · PHASE2
• Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) — COMPLETED · PHASE3
• A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups — COMPLETED · PHASE3
• Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia — COMPLETED · PHASE1
• Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype — OTHER

Refine this search